JOSE DANIEL SANCHEZ

Dr. JOSE DANIEL SANCHEZ

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2025 in Viruses
Verified
Journal Article
Open access
PDF file
JOSE DANIEL SANCHEZJOSE DANIEL SANCHEZ
JOSE DANIEL SANCHEZ
CRCarolina Álvarez Ramírez
Carolina Álvarez Ramírez
ECEmilio Cevallos Carrillo
Emilio Cevallos Carrillo
JSJuan Arias Salazar
Juan Arias Salazar
CCCésar Barros Cevallos
César Barros Cevallos
Background: Ecuador presents a unique epidemiological laboratory for studying arboviral dynamics due to its diverse ecological zones and exposure to climatic variability. Methods: We conducted a comprehensive 36-year analysis (1988–2024) of dengue (DENV), Zika (ZIKV), and chikungunya (CHIKV) using national surveillance data from Ecuador’s Ministry of Public Health. Statistical analyses included time series decomposition, change-point detection, correlation analysis, and climate association studies. Results: Ecuador reported 387,543 arboviral cases, with dengue comprising 91.3% (353,782 cases). Dengue exhibited endemic–epidemic cycles with major peaks during El Niño events (1994: 10,247 cases; 2000: 22,937 cases; 2015: 42,483 cases; 2024: 23,156 cases through week 26). CHIKV emerged explosively in 2015 (29,124 cases, incidence 181.10 per 100,000), followed by ZIKV in 2016 (2947 cases). Both showed rapid decline post-epidemic. Severe dengue cases paradoxically decreased from 2–4% of total cases in early 2000s to <0.1% post-2016, suggesting immunological modulation. Cross-correlation analysis revealed significant associations between climatic indices and epidemic timing (r=0.67, p<0.001), particularly for the El Niño-Southern Oscillation. Conclusions: Arboviral diseases in Ecuador function as an integrated epidemiological system with evidence of viral interactions, cross-protective immunity, and strong climate forcing. These findings emphasize the need for integrated surveillance and adaptive control strategies.

28 November 2025 in Discover Education
Verified
Journal Article
Open access
PDF file
SRSánchez- Redroban
Sánchez- Redroban
JOSE DANIEL SANCHEZJOSE DANIEL SANCHEZ
JOSE DANIEL SANCHEZ
MRMonserrat Vanessa Romero-Duran
Monserrat Vanessa Romero-Duran
Problem-Based Learning (PBL) has evolved from its traditional roots into a sophisticated pedagogical approach enhanced by advanced digital technologies, including artificial intelligence as a subset of these digital innovations. This comprehensive framework provides medical educators with evidence-based guidance for implementing technology-enhanced PBL methodology, incorporating both traditional principles and modern technological tools. We synthesize current literature from 2019 to 2025, analyzing research findings to create actionable recommendations for educators seeking to implement or improve their PBL programs. Recent studies demonstrate significant improvements through technology integration: 34% enhancement in diagnostic accuracy (Yang et al. in J Pharm Educ Pract 12:112–120, 2024), 28% better knowledge retention (Yan et al. in BMC Med Educ 23:456, 2023), and 42% increase in student engagement (Matsuda and Izumi in Med Educ Online 29:2345, 678, 2024). The integration of virtual patients, simulation-based learning, and adaptive systems shows promising results in enhancing traditional PBL methodologies while maintaining core pedagogical principles. Our proposed framework addresses implementation planning, role definitions, assessment strategies, and quality assurance mechanisms that medical educators can immediately apply across diverse cultural and institutional contexts.

17 October 2025 in JMIRx Med
Verified
Journal Article
Open access
JOSE DANIEL SANCHEZJOSE DANIEL SANCHEZ
JOSE DANIEL SANCHEZ
ASAlejandro Arjuna Rodriguez Sr
Alejandro Arjuna Rodriguez Sr
KSKimberlly Pamela Montenegro Cuello Sr
Kimberlly Pamela Montenegro Cuello Sr
Background: The COVID-19 pandemic disrupted essential health care services globally, including routine childhood immunization programs. Ecuador faced significant challenges in maintaining vaccination coverage during this period. Objective: The aim of this study is to analyze the impact of the COVID-19 pandemic on routine childhood vaccination coverage in Ecuador by comparing prepandemic (2019) and pandemic (2020‐2021) data. Methods: This retrospective observational study analyzed vaccination coverage data from the Ministry of Public Health of Ecuador and demographic data from the National Institute of Statistics and Censuses. We examined routine childhood vaccination coverage for children under 24 months across all 24 provinces. Statistical analyses were performed using SPSS (version 28.0), including descriptive statistics and comparative analysis. Coverage rates were calculated as percentages of children in target age groups receiving recommended doses. Results: A significant decline in routine childhood vaccination coverage was observed during the pandemic. BCG vaccine coverage decreased from 86.4% in 2019 (n=286,569) to 80.7% in 2020 (n=266,961) and 75.3% in 2021 (n=248,812). Pentavalent vaccine third dose coverage dropped from 85.0% to 68.0% across the same period. The most dramatic decline was seen in measles-mumps-rubella vaccine second dose coverage, falling from 75.7% in 2019 to 58.4% in 2021. Coastal and highland provinces experienced the most severe reductions, with approximately 137,000 fewer doses administered in 2020 compared to stable prepandemic levels. Conclusions: The COVID-19 pandemic significantly impacted routine childhood vaccination coverage in Ecuador, with sustained declines through 2021. Regional disparities were evident, with vulnerable populations facing greater challenges accessing immunization services. Urgent interventions, including catch-up campaigns and strengthened health systems, are needed to restore coverage levels and prevent outbreaks of vaccine-preventable diseases.

24 April 2026 in Tropical Medicine and Health
Verified
Journal Article
Open access
JOSE DANIEL SANCHEZJOSE DANIEL SANCHEZ
JOSE DANIEL SANCHEZ
Neglected tropical diseases (NTDs) represent a profound market failure wherein pharmaceutical innovation systematically underserves populations with the greatest need. Despite affecting over 1.7 billion people globally, NTDs receive less than 2% of pharmaceutical research and development (R&D) investment. This review synthesises evidence on the pharmaceutical industry's evolving role in NTD control, examining both traditional commercial models and innovative partnerships that have reshaped the global health landscape, with particular attention to implementation mechanisms and concrete operational pathways. We conducted a comprehensive analysis of WHO reports, G-FINDER data, peer-reviewed literature, and industry commitments spanning 2000-2024, focusing on drug development pipelines, mass drug administration programmes, and financing mechanisms. Product Development Partnerships (PDPs) have delivered 183 approved products since 1999, though the majority represent reformulations or repurposed compounds rather than novel chemical entities (NCEs). Mass drug administration programmes have distributed over 17 billion treatments from pharmaceutical donations valued at approximately $30 billion (at wholesale prices), preventing millions of disability-adjusted life years. However, persistent innovation gaps remain: only 4 NCEs (0.5% of all new therapeutics 2000-2011) specifically targeted NTDs. Diagnostic development continues to lag due to commercial barriers and fragmented regulatory pathways. The pharmaceutical industry's contribution to NTD control has evolved from minimal engagement to strategic partnerships blending philanthropic drug donation, nonprofit-led R&D, and market-based incentives. While mechanisms including Priority Review Vouchers and Advance Market Commitments show potential, their effectiveness remains debated in the literature, particularly regarding access provisions and additionality. Future progress requires sustained push funding for PDPs, multi-year donor commitments, expansion of WHO prequalification for diagnostics, and strengthened South-South technology-transfer partnerships with concrete implementation frameworks.

5 June 2025 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
CTCarlos Perez Tulcanaza
Carlos Perez Tulcanaza
ABAndré Benítez-Baldassari
André Benítez-Baldassari
ABAndrea Banegas-Sarmiento
Andrea Banegas-Sarmiento
JOSE DANIEL SANCHEZJOSE DANIEL SANCHEZ
JOSE DANIEL SANCHEZ
Background: Anemia represents a significant complication in patients with advanced chronic kidney disease (CKD) on hemodialysis, primarily caused by reduced renal erythropoietin production. Despite erythropoiesis-stimulating agents (ESAs) being the cornerstone of treatment, hyporesponsiveness to these agents remains a clinical challenge with implications for patient outcomes. Objective: To identify and quantify risk factors associated with hyporesponsiveness to erythropoietin in patients with CKD on hemodialysis who present with anemia. Methods: This multicenter case–control study analyzed data from 784 hemodialysis patients receiving erythropoietin therapy across six dialysis centers in Ecuador between January and December 2019. Hyporesponsiveness was defined as requiring ≥ 200 IU/kg/week of erythropoietin alfa for ≥3 consecutive months to maintain target hemoglobin levels (10–12 g/dL). Demographic, clinical, and laboratory parameters were compared between hyporesponsive cases (n = 123) and responsive controls (n = 661). Bivariate and multivariate logistic regression analyses were performed to identify independent risk factors. Results: The prevalence of erythropoietin hyporesponsiveness was 15.69%. A multivariate analysis identified female sex (adjusted OR = 1.96; 95% CI: 1.20–3.20; p < 0.001), age < 50 years (adjusted OR = 4.25; 95% CI: 2.42–7.47; p < 0.001), serum albumin < 4.0 g/dL (adjusted OR = 10.53; 95% CI: 6.53–16.98; p < 0.001), ferritin ≥ 800 ng/mL (adjusted OR = 7.28; 95% CI: 4.22–12.57; p < 0.001), transferrin saturation < 20% (adjusted OR = 9.27; 95% CI: 5.47–15.69; p < 0.001), parathyroid hormone ≥ 500 pg/mL (adjusted OR = 1.89; 95% CI: 1.16–3.09; p = 0.011), and use of renin–angiotensin system blockers (adjusted OR = 2.25; 95% CI: 1.36–3.71; p = 0.002) as independent risk factors for erythropoietin hyporesponsiveness. Conclusions: Multiple demographic, clinical, and laboratory factors independently contribute to erythropoietin hyporesponsiveness in hemodialysis patients. Identification of these risk factors may guide clinicians in developing individualized treatment approaches, optimizing erythropoietin dosing, and implementing targeted interventions to improve anemia management in this vulnerable population.

20 November 2025 in Public Health Challenges
Verified
Journal Article
Open access
SASonia Argote
Sonia Argote
DBDoménica Bucheli
Doménica Bucheli
APAshel Páez
Ashel Páez
CRCamila Rovayo
Camila Rovayo
DFDaniel Freire
Daniel Freire
JOSE DANIEL SANCHEZJOSE DANIEL SANCHEZ
JOSE DANIEL SANCHEZ
Objective: To evaluate the prevalence and determinants of analgesic self‐medication among university students in Ecuador, with a focus on the interplay between pharmacological knowledge and personal attitudes. Methods: A cross‐sectional analytical study was conducted with 422 students at Universidad Tecnologica Indoamerica (April–August 2025), selected via stratified random sampling. A validated, structured questionnaire assessed knowledge, attitudes, and practices. Multivariable logistic regression and random forest algorithms were employed to identify key predictors and their relative importance. Results: The prevalence of analgesic self‐medication was exceptionally high at 87.5%. Random forest analysis identified attitude as the primary predictor of this behavior (relative importance = 0.252), followed by academic year and pharmacological knowledge. A significant “knowledge–attitude paradox” was observed, wherein health sciences students, despite possessing superior pharmacological knowledge, exhibited the highest rates of self‐medication. The predictive model demonstrated excellent discrimination (AUC = 0.81). Conclusion: The high prevalence of self‐medication, a finding consistent with emerging international data, necessitates a fundamental paradigm shift in public health interventions. Educational strategies must evolve beyond simple information dissemination to incorporate behavioral science principles aimed at modifying attitudes and risk perceptions, particularly during the formative early years of university education.